Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy.
Inhibiting angiogenesis has become a major therapeutic strategy for cancer treatment. To identify common intracellular mediators, we previously analyzed gene expression profiles of endothelial cells after treatment with angiogenesis inhibitors. Filamin A interacting protein 1-like (FILIP1L; previously known as down-regulated in ovarian cancer 1) was identified as one of the genes up-regulated in endothelial cells in response to these inhibitors. However, the expression and function of FILIP1L protein is uncharacterized. Here, we provide the first description of the expression and specific subcellular localization of FILIP1L protein in human tissue. Overexpression of FILIP1L resulted in inhibition of cell proliferation and migration and increased apoptosis. In addition, overexpression of FILIP1L truncation mutants showed differential antiproliferative activity. A COOH terminal truncation mutant (FILIP1LDeltaC103) was more potent than wild-type FILIP1L in mediating this activity. Targeted expression of FILIP1LDeltaC103 in tumor vasculature inhibited tumor growth in vivo. Overall, these findings suggest that the novel protein FILIP1L may be an important mediator of the effects of angiogenesis inhibitors and that FILIP1L has the potential to be an antivascular reagent for cancer therapy.
Kwon
Mijung
M
Tumor Angiogenesis Section, Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.
Hanna
Engy
E
Lorang
Dominique
D
He
Mei
M
Quick
John S
JS
Adem
Asha
A
Stevenson
Christina
C
Chung
Joon-Yong
JY
Hewitt
Stephen M
SM
Zudaire
Enrique
E
Esposito
Dominic
D
Cuttitta
Frank
F
Libutti
Steven K
SK
D000818:Animals; D017209:Apoptosis / Q000502:physiology; D048708:Cell Growth Processes / Q000502:physiology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000502:physiology; D003110:Colonic Neoplasms / Q000098:blood supply* / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D016207:Cytokines / Q000096:biosynthesis* / Q000235:genetics* / Q000378:metabolism; D018076:DNA, Complementary / Q000235:genetics; D043169:Endostatins / Q000494:pharmacology; D042783:Endothelial Cells / Q000378:metabolism / Q000473:pathology / Q000502:physiology; D005260:Female; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D008297:Male; D008545:Melanoma / Q000098:blood supply* / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D051379:Mice; D009389:Neovascularization, Pathologic / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D013347:Subcellular Fractions / Q000378:metabolism; D014162:Transfection; D015854:Up-Regulation / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
D016207:Cytokines; D018076:DNA, Complementary; D043169:Endostatins; C504459:FILIP1L protein, human; D047908:Intracellular Signaling Peptides and Proteins
Cancer Res. 2003 Oct 1;63(19):6405-12
14559830
Cancer Sci. 2006 Dec;97(12):1359-65
16999820
Curr Opin Mol Ther. 2004 Feb;6(1):54-70
15011782
Neoplasia. 2005 Sep;7(9):816-23
16229804
Cancer Res. 1998 Aug 15;58(16):3751-6
9721889
Nature. 1993 Dec 9;366(6455):591-2
8255299
Cell. 1997 Jan 24;88(2):277-85
9008168
J Biol Chem. 1994 Oct 7;269(40):25106-19
7929199
J Biol Chem. 2001 May 25;276(21):17871-7
11278410
J Biol Chem. 1992 Oct 5;267(28):20239-47
1400342
Nat Protoc. 2007;2(2):416-23
17406603
Science. 1999 Apr 2;284(5411):147-51
10102815
Biochemistry (Mosc). 2007 Mar;72(3):235-46
17447877
Nat Cell Biol. 2002 Jul;4(7):495-501
12055638
Trends Cardiovasc Med. 2006 Apr;16(3):80-8
16546688
Cancer Metastasis Rev. 1992 Mar;11(1):69-77
1511498
Clin Cancer Res. 2008 Jan 1;14(1):270-80
18172279
J Biol Chem. 2002 Jun 14;277(24):21998-2009
11909861
J Virol. 2006 Feb;80(4):1922-38
16439548
J Immunother. 2000 Sep-Oct;23(5):519-27
11001545
Nat Protoc. 2007;2(3):523-31
17406616
Exp Cell Res. 2005 Dec 10;311(2):229-39
16248999
J Neurosci. 2004 Oct 27;24(43):9648-57
15509752
Nat Rev Mol Cell Biol. 2001 Feb;2(2):138-45
11252955
Cytokine. 2005 Jun 21;30(6):347-58
15935955
FEBS Lett. 2000 Dec 15;486(3):247-51
11119712
Nat Cell Biol. 2001 Dec;3(12):1060-8
11781567
Nat Cell Biol. 2007 Jul;9(7):838-46
17572668
J Biol Chem. 2000 Jan 7;275(1):271-8
10617615
J Biol Chem. 2003 Sep 26;278(39):37895-901
12851410
Cell. 2006 Apr 21;125(2):385-98
16630824
Nat Genet. 2003 Apr;33(4):487-91
12612583
Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1554-9
14747654
Nat Cell Biol. 2002 Sep;4(9):681-90
12198493
J Biol Chem. 2002 Apr 26;277(17):14877-83
11836256
Nature. 1990 Dec 6;348(6301):555-7
1701033
Genome Res. 2004 Aug;14(8):1585-93
15289477
Exp Cell Res. 2008 Feb 15;314(4):834-46
18177638
Curr Drug Targets. 2004 Jul;5(5):485-93
15216914
Nat Cell Biol. 2006 Aug;8(8):803-14
16862148
J Biol Chem. 2003 Jan 10;278(2):1328-35
12376540
Neuron. 1998 Dec;21(6):1315-25
9883725
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6427-32
10841547
J Virol. 2002 Apr;76(7):3395-420
11884566
Cancer Res. 2002 Apr 1;62(7):1944-7
11929807
J Exp Med. 1999 Aug 2;190(3):341-54
10430623
Gynecol Oncol. 1994 Feb;52(2):247-52
8314147
J Cell Sci. 2004 Oct 1;117(Pt 21):5013-22
15383615
Nat Cell Biol. 2000 Dec;2(12):888-92
11146652
Cancer Lett. 2003 Jun 30;196(1):1-12
12860282